Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 11/20 | 0.77 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.77 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.77 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.77 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.77 |
| ▸ | SRC | P12931 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.77 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.77 |
| ▸ | LDHA | P00338 | 1/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.77 |
| ▸ | FBP1 | P09467 | 1/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.77 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.77 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.77 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioinosine Monophosphate SCHEMBL29746215 | 1.00 | DNPH1 (0.77) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| Thioinosine Monophosphate SCHEMBL15810629 | 1.00 | DNPH1 (0.77) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| Thioinosine Monophosphate SCHEMBL379365 | 1.00 | DNPH1 (0.77) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| Thioinosine Monophosphate SCHEMBL8711009 | 0.96 | DNPH1 (0.72) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| SCHEMBL1905818 | 0.92 | P2RX3 (0.72) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| SCHEMBL1905822 | 0.92 | P2RX3 (0.72) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| SCHEMBL1906288 | 0.91 | P2RY1 (0.74) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| SCHEMBL1906291 | 0.91 | P2RY1 (0.74) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| Thioinosine Monophosphate SCHEMBL6368891 | 0.91 | ADORA1 (0.68) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 | |
| SCHEMBL3859612 | 0.90 | P2RY1 (0.67) | DNPH1P2RY1TAS1R3TAS1R1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295671-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2025-09-25 | — | — | US | claimed |
| US-12357642-B2 | Hazardous agent injection system | ANTARES PHARMA, INC. (US) | 2025-07-15 | — | — | US | claimed |
| EP-4427737-A2 | HAZARDOUS AGENT INJECTION SYSTEM | Antares Pharma, Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| US-20230104341-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2023-04-06 | — | — | US | claimed |
| US-11497753-B2 | Hazardous agent injection system | ANTARES PHARMA, INC. (US) | 2022-11-15 | — | — | US | claimed |
| US-20200163975-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2020-05-28 | — | — | US | claimed |
| US-20170361021-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2017-12-21 | — | — | US | claimed |
| US-20170043093-A1 | Hazardous Agent Injection System | ASSERTIO SPECIALTY PHARMACEUTICALS, LLC | 2017-02-16 | — | — | US | claimed |
| US-20150119799-A1 | Hazardous Agent Injection System | ASSERTIO SPECIALTY PHARMACEUTICALS, LLC | 2015-04-30 | — | — | US | claimed |
| WO-2014165136-A1 | CONSTANT VOLUME PREFILLED SYRINGES AND KITS THEREOF | ANTARES PHARMA, INC. (US) | 2014-10-09 | — | — | WO | claimed |
| EP-2408493-A1 | HAZARDOUS AGENT INJECTION SYSTEM | Antares Pharma, Inc. (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2010108116-A1 | HAZARDOUS AGENT INJECTION SYSTEM | ANTARES PHARMA, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| US-12629483-B2 | Syringe shock absorber for use in an injection device | ANTARES PHARMA, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12629482-B2 | Syringe shock absorber for use in an injection device | ANTARES PHARMA, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12576213-B2 | Multiple dosage injector with rack and pinion dosage system having ram that includes a lockout protrusion | ANTARES PHARMA, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260034313-A1 | SYRINGE SHOCK ABSORBER FOR USE IN AN INJECTION DEVICE | ANTARES PHARMA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-6355623-B2 | DETERMINING THE LEVEL OF 6-THIOGUANINE METABOLITE WHEREIN A LEVEL OF 6-THIOGUANINE LESS THAN ABOUT 230 PMOL PER 8 X 108 RED BLOOD CELLS INDICATES A DRUG INCREASE; A LEVEL OF 400PMOL INDICATES A DECREASE; NONTOXIC | HOPITAL-SAINTE-JUSTINE (CA) | 2002-03-12 | — | — | US | disclosed |
| EP-1115403-A1 | OPTIMIZED USE OF 6-MERCAPTOPURINE DRUG IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | Hospital Sainte-Justine (CA) | 2001-07-18 | — | — | EP | disclosed |
| US-20010006970-A1 | Determining the level of 6-thioguanine metabolite wherein a level of 6-thioguanine less than about 230 pmol per 8 x 108 red blood cells indicates a drug increase; a level of 400pmol indicates a decrease; nontoxic | HOPITAL SAINTE-JUSTINE | 2001-07-05 | — | — | US | disclosed |
| WO-2000016780-A1 | OPTIMIZED USE OF 6-MERCAPTOPURINE DRUG IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | HOPITAL SAINTE-JUSTINE (CA) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043093-A1 | Hazardous Agent Injection System | TIAL1, AHSA1, GYS2 | DNPH1 505/4885P2RY1 613/4885TAS1R3 3694/4885 |
| US-20230104341-A1 | Hazardous Agent Injection System | TIAL1, AHSA1, GYS2 | DNPH1 505/4885P2RY1 613/4885TAS1R3 3694/4885 |
| US-12576213-B2 | Multiple dosage injector with rack and pinion dosage system having ram that includes a lockout protrusion | RACK1, DYNLL1, TRAF6 | DNPH1 3538/4885P2RY1 944/4885TAS1R3 1340/4885 |
| US-20150119799-A1 | Hazardous Agent Injection System | TIAL1, AHSA1, GYS2 | DNPH1 505/4885P2RY1 613/4885TAS1R3 3694/4885 |
| US-11497753-B2 | Hazardous agent injection system | TIAL1, AHSA1, GYS2 | DNPH1 505/4885P2RY1 613/4885TAS1R3 3694/4885 |
| US-20250295671-A1 | Hazardous Agent Injection System | TIAL1, AHSA1, GYS2 | DNPH1 505/4885P2RY1 613/4885TAS1R3 3694/4885 |
| US-20170361021-A1 | Hazardous Agent Injection System | TIAL1, AHSA1, GYS2 | DNPH1 505/4885P2RY1 613/4885TAS1R3 3694/4885 |
| US-20260034313-A1 | SYRINGE SHOCK ABSORBER FOR USE IN AN INJECTION DEVICE | CRH, SSTR5, CLPP | DNPH1 2917/4885P2RY1 794/4885TAS1R3 3147/4885 |
| US-12629482-B2 | Syringe shock absorber for use in an injection device | SLC6A4, SLC47A2, ABCB11 | DNPH1 4076/4885P2RY1 1026/4885TAS1R3 2425/4885 |
| US-12629483-B2 | Syringe shock absorber for use in an injection device | SLC6A4, SSTR4, SLC6A2 | DNPH1 3130/4885P2RY1 486/4885TAS1R3 3035/4885 |
| US-20200163975-A1 | Hazardous Agent Injection System | TIAL1, AHSA1, GYS2 | DNPH1 505/4885P2RY1 613/4885TAS1R3 3694/4885 |
| US-12357642-B2 | Hazardous agent injection system | TIAL1, AHSA1, GYS2 | DNPH1 505/4885P2RY1 613/4885TAS1R3 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.